• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Silvergate Capital Corporation filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Other Events

    5/11/23 8:30:36 AM ET
    $SI
    Medical/Dental Instruments
    Health Care
    Get the next $SI alert in real time by email
    falseSilvergate Capital Corp0001312109CASIPRA00013121092023-05-112023-05-110001312109us-gaap:CommonClassAMember2023-05-112023-05-110001312109sipra:DepositarySharesEachRepresentingA140thInterestInAShareOf5375FixedRateNonCumulativePerpetualPreferredStockSeriesAMember2023-05-112023-05-11


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM 8-K

    CURRENT REPORT
    PURSUANT TO SECTION 13 OR 15(d) OF THE
    SECURITIES EXCHANGE ACT OF 1934

    Date of Report (Date of earliest event reported): May 11, 2023

    SILVERGATE CAPITAL CORPORATION
    (Exact name of registrant as specified in its charter)
     
    Maryland
    001-39123
    33-0227337
    (State or other jurisdiction of
    (Commission file number)
    (IRS Employer
    incorporation or organization)
     
    Identification No.)

    4250 Executive Square, Suite 300, La Jolla, CA 92037
    (Address of principal executive offices) (Zip Code)

    (858) 362-6300
    (Registrant’s telephone number, including area code)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

    ☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of Each Class
    Trading Symbol
    Name of Each Exchange on Which Registered
    Class A Common Stock, par value $0.01 per share
    SI
    New York Stock Exchange
    Depositary Shares, Each Representing a 1/40th Interest in a Share of 5.375% Fixed Rate Non-Cumulative Perpetual Preferred Stock, Series A
    SI PRA
    New York Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company        ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.             ☐




    ITEM 2.05          COSTS ASSOCIATED WITH EXIT OR DISPOSAL ACTIVITIES.

    Beginning on May 12, 2023, Silvergate Capital Corporation (the “Company”) will undertake additional reductions in headcount, which reductions will ultimately reduce substantially all of its headcount.  Effective on May 12, 2023, approximately 230 employees will be separated.  Additional incremental reductions in headcount are expected to occur on each of June 30, 2023, August 30, 2023 and November 30, 2023 or later.  These actions are taken in connection with the previously disclosed efforts to wind down operations and voluntarily liquidate the Company’s wholly-owned subsidiary, Silvergate Bank (the “Bank”), in an orderly manner and in accordance with applicable regulatory processes (the “Bank Liquidation”).

    Following the reduction effective in May, the remaining approximately 80 officers and employees will focus on implementing the Bank Liquidation, preserving the residual value of the Company’s assets and addressing the regulatory and other inquiries and investigations that are pending with respect to the Company and the Bank.

    Impacted employees have been notified, and the Company is providing certain of these individuals with severance packages, retention bonuses and job placement resources.  The Company estimates aggregate costs associated with these reductions in force of approximately $13.6 million, including approximately $10.7 million in severance and retention bonus payments and $2.8 million in employee benefits and job placement expenses.


    ITEM 8.01          OTHER EVENTS.

    Exchange Act Filings

    As disclosed in the Form 12b-25 filed by the Company on May 11, 2023, the Company is unable to file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 and its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “2022 10-K”), and does not expect to be able to file any Quarterly Reports on Form 10-Q or Annual Reports on Form 10-K for subsequent periods or its definitive proxy statement for 2023.  As a result of the Bank Liquidation, the Company determined that it is in the best interests of the Company and relevant stakeholders to minimize costs and expenses in order to preserve value for stakeholders.  In making this determination, the Company considered, among other matters, the challenges associated with completing an audit of the Company’s financial statements for the year ended December 31, 2022.  Specifically, due to the continuous developments relating to the regulatory and other inquiries and investigations that are pending with respect to the Company and the Bank, the potential liabilities resulting from various litigation with respect to the Company (including private litigation) and the Bank Liquidation, the Company’s independent registered public accounting firm has been unable to complete its audit procedures for the 2022 Form 10-K, and is not currently working on any such audit procedures or any review of subsequent financial statements of the Company.  Accordingly, the Company authorized the reduction in workforce (including a reduction in the personnel in financial reporting functions who are critical to the preparation of such filings) described in Item 2.05 of this Current Report on Form 8-K to align the Company’s overall staffing with (i) the objectives of the Bank Liquidation and (ii) the Company’s determination of the best path to (A) efficiently resolve claims and preserve the residual value of its assets and (B) avoid the overwhelming challenges associated with completing a financial statement audit in accordance with applicable standards.

    As previously disclosed, on March 17, 2023, the Company was notified by the New York Stock Exchange (the “NYSE”) that, as the Company had not timely filed the 2022 10-K, the NYSE would monitor the status of the Company’s late filing and related public disclosures for up to a six-month period from its due date, but that the NYSE could, in its sole discretion, commence delisting proceedings at any time during the period that is available to complete the filing, if circumstances warrant.  The Company recently informed the NYSE that it will not file the 2022 10-K or any subsequent periodic reports as required by Section 13(a) or 15(d) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).  As a result, the NYSE has suspended trading in the Company’s securities and has indicated to the Company that it expects to commence delisting of the Company’s securities shortly thereafter.

    Financial Update

    In connection with the Bank Liquidation process, as of the date hereof, the Bank has completed sales of all of its debt securities.  In addition, in March 2023, the Bank fully repaid its outstanding borrowings from the Federal Home Loan Bank.  As of May 9, 2023, the Company had cash and cash equivalents in excess of the amounts required to fully repay all remaining deposit liabilities of the Bank.  However, the Company has potential contingent liabilities related to, among other things, the regulatory and other inquiries and investigations that are pending with respect to the Company and the Bank, the various litigation with respect to the Company (including private litigation) and other expenses to be incurred in connection with operating the Bank through the Bank Liquidation (including expenses necessary for the operation of the Company and/or the Bank, employee benefits and compensation and fees and expenses of professionals retained by the Company in connection with the Bank Liquidation) and is unable to quantify such amounts at this time.



    Forward-Looking Statements

    Statements in this Current Report on Form 8-K may constitute forward-looking statements within the meaning of the Exchange Act. These forward-looking statements reflect our current views with respect to, among other things, the Bank Liquidation and the regulatory and other inquiries and investigations that are pending with respect to the Company and the Bank, future events and our financial performance. These statements are often, but not always, made through the use of words or phrases such as “may,” “should,” “could,” “predict,” “potential,” “believe,” “will likely result,” “expect,” “continue,” “will,” “anticipate,” “seek,” “estimate,” “intend,” “plan,” “project,” “projection,” “forecast,” “goal,” “target,” “would,” “aim” and “outlook,” or the negative version of those words or other comparable words or phrases of a future or forward-looking nature. These forward-looking statements are not historical facts, and are based on current expectations, estimates and projections about our industry and management’s beliefs and certain assumptions made by management, many of which, by their nature, are inherently uncertain and beyond our control. The inclusion of these forward-looking statements should not be regarded as a representation by us or any other person that such expectations, estimates and projections will be achieved. Although we believe that the expectations reflected in these forward-looking statements are reasonable as of the date made, such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions and uncertainties that are difficult to predict. For information about other important factors that could cause actual results to differ materially from those discussed in the forward-looking statements contained in this release, please refer to the Company’s public reports filed with the SEC.

    Any forward-looking statement speaks only as of the date of this Current Report on Form 8-K, and we do not undertake any obligation to publicly update or review any forward-looking statement, whether because of new information, future developments or otherwise, except as required by law. New risks and uncertainties may emerge from time to time, and it is not possible for us to predict their occurrence. In addition, we cannot assess the impact of each risk and uncertainty on our business or the extent to which any risk or uncertainty, or combination of risks and uncertainties, may cause actual results to differ materially from those contained in any forward-looking statements.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


       
    SILVERGATE CAPITAL CORPORATION
         
    Date:  May 11, 2023
    By:
    /s/ Alan J. Lane
     
         
    Name:
    Alan J. Lane
     
         
    Title:
    Chief Executive Officer
     


    Get the next $SI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SI

    DatePrice TargetRatingAnalyst
    8/25/2025$20.00Buy
    Goldman
    8/25/2025$23.00Buy
    BTIG Research
    8/25/2025$18.00Overweight
    Piper Sandler
    8/25/2025$19.00Buy
    Jefferies
    3/6/2023Neutral → Sell
    Compass Point
    3/6/2023$9.00 → $4.00Neutral → Underperform
    Wedbush
    3/2/2023$16.00 → $10.00Buy → Neutral
    Compass Point
    3/2/2023Neutral → Underweight
    JP Morgan
    More analyst ratings

    $SI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Points Jeffrey S. bought $29,632 worth of shares (2,000 units at $14.82), increasing direct ownership by 4% to 54,445 units (SEC Form 4)

    4 - SHOULDER INNOVATIONS, INC. (0001699350) (Issuer)

    12/15/25 4:57:01 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    CEO & Executive Chairman Ball Robert Joseph bought $107,009 worth of shares (7,200 units at $14.86), increasing direct ownership by 6% to 118,457 units (SEC Form 4)

    4 - SHOULDER INNOVATIONS, INC. (0001699350) (Issuer)

    12/15/25 4:51:45 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    CHIEF FINANCIAL OFFICER Points Jeffrey S. exercised 13,264 shares at a strike of $2.48 and bought $25,072 worth of shares (1,600 units at $15.67), increasing direct ownership by 40% to 52,445 units (SEC Form 4)

    4 - SHOULDER INNOVATIONS, INC. (0001699350) (Issuer)

    9/15/25 4:25:01 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    $SI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Points Jeffrey S.

    4 - SHOULDER INNOVATIONS, INC. (0001699350) (Issuer)

    2/3/26 4:43:22 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Officer Blue David Lawrence

    4 - SHOULDER INNOVATIONS, INC. (0001699350) (Issuer)

    2/3/26 4:39:36 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by CEO & Executive Chairman Ball Robert Joseph

    4 - SHOULDER INNOVATIONS, INC. (0001699350) (Issuer)

    2/3/26 4:35:28 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    $SI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Shoulder Innovations to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

    GRAND RAPIDS, Mich., Feb. 3, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. (Shoulder Innovations, or the Company) (NYSE:SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced that members of management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UT on Tuesday, February 10, 2026 and Wednesday, February 11, 2026.  About Shoulder InnovationsShoulder Innovations is a commercial-stage medical technology company exclusivel

    2/3/26 4:05:00 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    Impulse Dynamics® Announces New Chief Financial Officer

    MARLTON, N.J., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Impulse Dynamics®, a global medical device company committed to improving the lives of people with heart failure (HF), announced today the appointment of Richard J. Buchholz as its new Chief Financial Officer (CFO), effective March 2, 2026. "Rick is an accomplished executive with a proven track record in the medical device industry," said Jason Spees, Chief Executive Officer at Impulse Dynamics®. "I am thrilled to welcome Rick to the Impulse Dynamics® team at a time when we are poised for our next phase of growth as we continue to advance our mission of improving patients' lives." Buchholz most recently served as the CFO for Inspire Medi

    1/13/26 9:00:00 AM ET
    $INSP
    $SI
    Medical/Dental Instruments
    Health Care

    Shoulder Innovations Announces Strategic Partnership with INS to Introduce a Robotic Platform for Shoulder Arthroplasty

    Partnership will Expand Shoulder Innovations' Disruptive Ecosystem with Advanced Enabling Technology, Complementing Surgeon and Patient Needs in the ASC Management to Participate in a Fireside Chat at the Piper Sandler 37th Annual Healthcare Conference Today at 8:30 a.m. ET GRAND RAPIDS, Mich., Dec. 3, 2025 /PRNewswire/ -- Shoulder Innovations, Inc. (Shoulder Innovations, or the Company) (NYSE:SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced a strategic partnership with Interventional Systems (INS), a developer of robotic solutions for minimally invasive surgery, to introduce a transformative shoulder-s

    12/3/25 7:00:00 AM ET
    $SI
    Medical/Dental Instruments
    Health Care

    $SI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman initiated coverage on Shoulder Innovations with a new price target

    Goldman initiated coverage of Shoulder Innovations with a rating of Buy and set a new price target of $20.00

    8/25/25 8:23:10 AM ET
    $SI
    Medical/Dental Instruments
    Health Care

    Piper Sandler initiated coverage on Shoulder Innovations with a new price target

    Piper Sandler initiated coverage of Shoulder Innovations with a rating of Overweight and set a new price target of $18.00

    8/25/25 8:22:49 AM ET
    $SI
    Medical/Dental Instruments
    Health Care

    BTIG Research initiated coverage on Shoulder Innovations with a new price target

    BTIG Research initiated coverage of Shoulder Innovations with a rating of Buy and set a new price target of $23.00

    8/25/25 8:22:49 AM ET
    $SI
    Medical/Dental Instruments
    Health Care

    $SI
    SEC Filings

    View All

    Shoulder Innovations Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - SHOULDER INNOVATIONS, INC. (0001699350) (Filer)

    12/3/25 7:10:53 AM ET
    $SI
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Shoulder Innovations Inc.

    10-Q - SHOULDER INNOVATIONS, INC. (0001699350) (Filer)

    11/12/25 4:10:24 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    Shoulder Innovations Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - SHOULDER INNOVATIONS, INC. (0001699350) (Filer)

    11/12/25 9:13:28 AM ET
    $SI
    Medical/Dental Instruments
    Health Care

    $SI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Silvergate Capital Corporation (Amendment)

    SC 13G/A - Silvergate Capital Corp (0001312109) (Subject)

    2/12/24 12:17:13 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Silvergate Capital Corporation (Amendment)

    SC 13G/A - Silvergate Capital Corp (0001312109) (Subject)

    5/22/23 4:03:17 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Silvergate Capital Corporation

    SC 13G - Silvergate Capital Corp (0001312109) (Subject)

    2/14/23 4:49:34 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    $SI
    Leadership Updates

    Live Leadership Updates

    View All

    Silvergate announces changes to its executive team

    Silvergate Capital Corporation (the "Company" or "Silvergate") (NYSE:SI), the leading provider of innovative financial infrastructure solutions to the digital asset industry, today announced the promotion of Ben Reynolds to President, and appointment of Kate Fraher as Chief Risk Officer, of both the Company and its subsidiary, Silvergate Bank. In their new roles, Ben and Kate will continue reporting to Alan Lane, CEO of Silvergate and the bank. "We are excited about these new roles, which will benefit Silvergate as we continue to grow and mature as an organization," said Alan Lane, CEO of Silvergate. "Serving the digital asset industry requires that we continue to innovate and deliver prod

    11/7/22 4:30:00 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    Silvergate Announces Appointment of Mary-Margaret Henke to Board of Directors

    Silvergate Capital Corporation (the "Company" or "Silvergate") (NYSE:SI), the leading provider of innovative financial infrastructure solutions to the digital currency industry, today announced the appointment of Mary-Margaret Henke to the board of directors of both the Company and its subsidiary bank, Silvergate Bank. "I am fortunate to be joining Silvergate's board during this period of continued evolution for both the bank and the digital assets industry," said Mary-Margaret Henke. "I look forward to working in tandem with my fellow Board members and management to ensure the Company remains a leader in innovative banking solutions." "Mary-Margaret's extensive knowledge of the financial

    9/19/22 4:15:00 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    Silvergate Announces Appointment of Rebecca Rettig to Board of Directors

    Silvergate Capital Corporation (the "Company" or "Silvergate") (NYSE:SI), the leading provider of innovative financial infrastructure solutions to the digital currency industry, today announced the appointment of Rebecca Rettig to the board of directors for both the Company and its subsidiary bank, Silvergate Bank. "I am honored to join Silvergate's board at this moment of evolution in the bank's history and the digital asset ecosystem," said Rebecca Rettig. "I look forward to working with Silvergate's leadership and my fellow board members to strengthen the Company's leadership position in this evolving and innovative industry." "Rebecca's broad wealth of knowledge in the blockchain and

    3/16/22 9:00:00 AM ET
    $SI
    Medical/Dental Instruments
    Health Care

    $SI
    Financials

    Live finance-specific insights

    View All

    Shoulder Innovations to Report Third Quarter 2025 Financial Results on November 11, 2025

    GRAND RAPIDS, Mich., Oct. 20, 2025 /PRNewswire/ -- Shoulder Innovations, Inc. ("Shoulder Innovations") (NYSE:SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced it will release financial results for the third quarter of 2025 after market close on Tuesday, November 11, 2025. Management will host a conference call to discuss financial results beginning at 4:30 p.m. ET / 1:30 p.m. PT on November 11, 2025. Those interested in listening to the conference call may do so by dialing (877) 407-8216 fo

    10/20/25 4:05:00 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    Shoulder Innovations to Report Second Quarter 2025 Financial Results on September 9, 2025

    Company to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on the Same Day GRAND RAPIDS, Mich., Aug. 28, 2025 /PRNewswire/ -- Shoulder Innovations, Inc. ("Shoulder Innovations") (NYSE:SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced it will release financial results for the second quarter of 2025 before market open on Tuesday, September 9, 2025. On the same day, members of management will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Hea

    8/28/25 4:05:00 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    Silvergate Suspends Series A Preferred Stock Dividend

    Silvergate Capital Corporation (the "Company" or "Silvergate") (NYSE:SI), the leading provider of innovative financial infrastructure solutions to the digital asset industry, today announced that the Company has suspended the payment of dividends on its 5.375% Fixed Rate Non-Cumulative Perpetual Preferred Stock, Series A, in order to preserve capital. This decision reflects the Company's focus on maintaining a highly liquid balance sheet with a strong capital position as it navigates recent volatility in the digital asset industry. The Company continues to maintain a cash position in excess of its digital asset customer related deposits. The Company's Board of Directors will re-evaluate th

    1/27/23 6:55:00 AM ET
    $SI
    Medical/Dental Instruments
    Health Care